Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004.

Slides:



Advertisements
Similar presentations
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Advertisements

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery  Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer  David R. Spigel,
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Estrogen Receptor (ER) and Epidermal Growth Factor Receptor (EGFR) as Targets for Dual Lung Cancer Therapy: Not Just a Case?  Monica Giovannini, MD, Carmen.
Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors  Su Jin Lee, MD, Jung-Il Lee,
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.
Standard Outcome Measures for Thymic Malignancies
Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia  Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,
An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging  Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer  Sarita Dubey, MD, Patricia Stephenson, ScD, Donna E. Levy,
The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition  Sai-Hong.
A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):
Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer  Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.
Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6  Paul J. Hesketh, MD, Rogerio C. Lilenbaum,
Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E
Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
Erratum Journal of Thoracic Oncology
Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab 
Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group.
Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q  Satoshi Watanabe, MD, PhD, Yuji Minegishi,
Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed  Emanuela Taioli, MD, PhD, Raja Flores, MD 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors 
The Port Site Recurrence after a Thoracoscopic and Video-Assisted Esophagectomy for Advanced Esophageal Cancer  Satoshi Yamamoto, PhD, Katsunobu Kawahara,
Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J
International Thymic Malignancies Interest Group: A Way Forward
Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma
Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non- small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin.
Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia.
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial  Barbara J.
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A
Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.
Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD 
Ana Luque, MD, Edurne Arriola, MD, PhD  Journal of Thoracic Oncology 
Presentation transcript:

Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: An Eastern Cooperative Oncology Group Study  Seena C. Aisner, MD, Suzanne Dahlberg, PhD, Meera R. Hameed, MD, David S. Ettinger, MD, Joan H. Schiller, MD, David H. Johnson, MD, Joseph Aisner, MD, Patrick J. Loehrer, MD  Journal of Thoracic Oncology  Volume 5, Issue 6, Pages 885-892 (June 2010) DOI: 10.1097/JTO.0b013e3181d86a30 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Progression-free survival by epidermal growth factor receptor (EGFR) group. Journal of Thoracic Oncology 2010 5, 885-892DOI: (10.1097/JTO.0b013e3181d86a30) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Progression-free survival by C-Kit group. Journal of Thoracic Oncology 2010 5, 885-892DOI: (10.1097/JTO.0b013e3181d86a30) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Overall survival by epidermal growth factor receptor (EGFR) group. Journal of Thoracic Oncology 2010 5, 885-892DOI: (10.1097/JTO.0b013e3181d86a30) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Overall survival by C-kit group. Journal of Thoracic Oncology 2010 5, 885-892DOI: (10.1097/JTO.0b013e3181d86a30) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions